CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ValiRx Plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ValiRx Plc
Eliot Park Innovation Centre
4 Barling Way
Phone: +44 2476796496p:+44 2476796496 NUNEATON, CV10 7RH  United Kingdom Ticker: VALVAL
Business Summary
ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board MartinGouldstone 57 7/25/2024 4/22/2024
Chief Executive Officer, Director Mark E.Eccleston 53 8/15/2024 8/15/2024
Chief Financial Officer, Executive Director, Company Secretary GeraldDesler 1/1/2022 5/12/2006
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Azure Holdings plc
Pharmatest Services Oy
Room Service Group plc
VAL
ValiFinn Oy

General Information
Number of Employees: 8 (As of 12/31/2022)
Outstanding Shares: 132,348,673 (As of 6/30/2024)
Shareholders: 2,690
Stock Exchange: LON
Fax Number: +44 2030084415


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024